S&P 500   3,390.46 (-2.16%)
DOW   27,605.53 (-2.58%)
QQQ   280.81 (-1.38%)
AAPL   114.95 (-0.08%)
MSFT   211.74 (-2.08%)
FB   280.32 (-1.57%)
GOOGL   1,597.97 (-2.14%)
AMZN   3,209.41 (+0.16%)
TSLA   418.28 (-0.56%)
NVDA   533.94 (-1.78%)
BABA   307.85 (-0.67%)
CGC   18.79 (-4.76%)
GE   7.43 (-2.62%)
MU   52.05 (-1.51%)
AMD   82.34 (+0.46%)
T   27.27 (-1.98%)
F   8.03 (-1.59%)
ACB   4.44 (-5.13%)
GILD   59.48 (-2.15%)
NFLX   485.06 (-0.66%)
NIO   26.45 (-2.61%)
BA   161.10 (-3.74%)
DIS   124.48 (-3.02%)
S&P 500   3,390.46 (-2.16%)
DOW   27,605.53 (-2.58%)
QQQ   280.81 (-1.38%)
AAPL   114.95 (-0.08%)
MSFT   211.74 (-2.08%)
FB   280.32 (-1.57%)
GOOGL   1,597.97 (-2.14%)
AMZN   3,209.41 (+0.16%)
TSLA   418.28 (-0.56%)
NVDA   533.94 (-1.78%)
BABA   307.85 (-0.67%)
CGC   18.79 (-4.76%)
GE   7.43 (-2.62%)
MU   52.05 (-1.51%)
AMD   82.34 (+0.46%)
T   27.27 (-1.98%)
F   8.03 (-1.59%)
ACB   4.44 (-5.13%)
GILD   59.48 (-2.15%)
NFLX   485.06 (-0.66%)
NIO   26.45 (-2.61%)
BA   161.10 (-3.74%)
DIS   124.48 (-3.02%)
S&P 500   3,390.46 (-2.16%)
DOW   27,605.53 (-2.58%)
QQQ   280.81 (-1.38%)
AAPL   114.95 (-0.08%)
MSFT   211.74 (-2.08%)
FB   280.32 (-1.57%)
GOOGL   1,597.97 (-2.14%)
AMZN   3,209.41 (+0.16%)
TSLA   418.28 (-0.56%)
NVDA   533.94 (-1.78%)
BABA   307.85 (-0.67%)
CGC   18.79 (-4.76%)
GE   7.43 (-2.62%)
MU   52.05 (-1.51%)
AMD   82.34 (+0.46%)
T   27.27 (-1.98%)
F   8.03 (-1.59%)
ACB   4.44 (-5.13%)
GILD   59.48 (-2.15%)
NFLX   485.06 (-0.66%)
NIO   26.45 (-2.61%)
BA   161.10 (-3.74%)
DIS   124.48 (-3.02%)
S&P 500   3,390.46 (-2.16%)
DOW   27,605.53 (-2.58%)
QQQ   280.81 (-1.38%)
AAPL   114.95 (-0.08%)
MSFT   211.74 (-2.08%)
FB   280.32 (-1.57%)
GOOGL   1,597.97 (-2.14%)
AMZN   3,209.41 (+0.16%)
TSLA   418.28 (-0.56%)
NVDA   533.94 (-1.78%)
BABA   307.85 (-0.67%)
CGC   18.79 (-4.76%)
GE   7.43 (-2.62%)
MU   52.05 (-1.51%)
AMD   82.34 (+0.46%)
T   27.27 (-1.98%)
F   8.03 (-1.59%)
ACB   4.44 (-5.13%)
GILD   59.48 (-2.15%)
NFLX   485.06 (-0.66%)
NIO   26.45 (-2.61%)
BA   161.10 (-3.74%)
DIS   124.48 (-3.02%)
Log in
NYSE:IQV

IQVIA Stock Forecast, Price & News

$160.94
-6.53 (-3.90 %)
(As of 10/26/2020 11:09 AM ET)
Add
Compare
Today's Range
$160.91
Now: $160.94▼
$165.68
50-Day Range
$148.07
MA: $160.43▼
$173.50
52-Week Range
$81.79
Now: $160.94▼
$176.00
Volume11,178 shs
Average Volume1.38 million shs
Market Capitalization$30.78 billion
P/E Ratio176.86
Dividend YieldN/A
Beta1.31
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Read More
IQVIA logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.48 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
Current SymbolNYSE:IQV
Previous Symbol
CUSIPN/A
CIK1478242
Webwww.iqvia.com
Phone919-998-2000
Employees67,000

Debt

Debt-to-Equity Ratio2.04
Current Ratio1.10
Quick Ratio1.09

Price-To-Earnings

Trailing P/E Ratio176.86
Forward P/E Ratio28.14
P/E Growth2.94

Sales & Book Value

Annual Sales$11.09 billion
Price / Sales2.78
Cash Flow$12.15 per share
Price / Cash Flow13.25
Book Value$32.28 per share
Price / Book4.99

Profitability

EPS (Most Recent Fiscal Year)$5.94
Net Income$191 million
Net Margins1.21%
Return on Equity17.90%
Return on Assets4.71%

Miscellaneous

Outstanding Shares191,271,000
Market Cap$30.78 billion
Next Earnings Date2/10/2021 (Estimated)
OptionableOptionable
$160.94
-6.53 (-3.90 %)
(As of 10/26/2020 11:09 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IQVIA (NYSE:IQV) Frequently Asked Questions

How has IQVIA's stock price been impacted by Coronavirus (COVID-19)?

IQVIA's stock was trading at $125.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IQV shares have increased by 30.7% and is now trading at $163.97.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of IQVIA?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 2 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IQVIA.

When is IQVIA's next earnings date?

IQVIA is scheduled to release its next quarterly earnings announcement on Wednesday, February 10th 2021.
View our earnings forecast for IQVIA.

How were IQVIA's earnings last quarter?

IQVIA Holdings Inc. (NYSE:IQV) announced its quarterly earnings data on Tuesday, October, 20th. The medical research company reported $1.63 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.52 by $0.11. The medical research company earned $2.79 billion during the quarter, compared to analysts' expectations of $2.75 billion. IQVIA had a return on equity of 17.90% and a net margin of 1.21%. The firm's revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.60 earnings per share.
View IQVIA's earnings history.

What guidance has IQVIA issued on next quarter's earnings?

IQVIA issued an update on its FY21 earnings guidance on Tuesday, October, 20th. The company provided EPS guidance of $7.65-7.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.57. The company issued revenue guidance of $12.3-12.6 billion, compared to the consensus revenue estimate of $12.23 billion.

What price target have analysts set for IQV?

18 Wall Street analysts have issued 1 year price objectives for IQVIA's stock. Their forecasts range from $110.00 to $224.00. On average, they expect IQVIA's stock price to reach $173.35 in the next year. This suggests a possible upside of 5.7% from the stock's current price.
View analysts' price targets for IQVIA.

Who are some of IQVIA's key competitors?

Some companies that are related to IQVIA include Incyte (INCY), Exact Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), ICON Public (ICLR), PRA Health Sciences (PRAH), Exelixis (EXEL), Syneos Health (SYNH), Medpace (MEDP), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA).
View all competitors.

What other stocks do shareholders of IQVIA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IQVIA investors own include CA (CA), BlackRock (BLK), NVIDIA (NVDA), Micron Technology (MU), Endologix (ELGX), Chipotle Mexican Grill (CMG), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM) and Accenture (ACN).

Who are IQVIA's key executives?

IQVIA's management team includes the following people:
  • Mr. Ari Bousbib, Chairman, Pres & CEO (Age 59, Pay $8.93M)
  • Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 56, Pay $1.11M)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 57, Pay $1.38M)
  • Mr. Kevin C. Knightly, Pres of Technology & Commercial Solutions (Age 59, Pay $1.18M)
  • Mr. Ronald E. Bruehlman, Exec. VP & Interim CFO (Age 59)
  • Mr. Emmanuel N. Korakis, Sr. VP, Corp. Controller & Principal Accounting Officer (Age 46)
  • Dr. Jeffrey A. Spaeder, Sr. VP, Global Chief Medical & Scientific Officer
  • Mr. Alejandro Martinez, Chief Information Officer
  • Andrew Markwick, Sr. VP of Investor Relations & Treasury
  • Ms. Marla L. Kessler, Sr. VP of Strategy, Marketing & Communications (Age 50)

What is IQVIA's stock symbol?

IQVIA trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Who are IQVIA's major shareholders?

IQVIA's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.18%), Retirement Systems of Alabama (0.13%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.12%), DNB Asset Management AS (0.06%), McGuire Investment Group LLC (0.04%) and Standard Life Aberdeen plc (0.03%). Company insiders that own IQVIA stock include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, John Connaughton, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer, Ronald E Bruehlman and W Richard Staub.
View institutional ownership trends for IQVIA.

Which institutional investors are selling IQVIA stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Redpoint Investment Management Pty Ltd, Standard Life Aberdeen plc, Gradient Investments LLC, Nissay Asset Management Corp Japan ADV, Pacer Advisors Inc., First Hawaiian Bank, and NEXT Financial Group Inc. Company insiders that have sold IQVIA company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Michael J Evanisko, and Michael R Mcdonnell.
View insider buying and selling activity for IQVIA.

Which institutional investors are buying IQVIA stock?

IQV stock was bought by a variety of institutional investors in the last quarter, including CWM LLC, Envestnet Asset Management Inc., Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Community Trust & Investment Co., DNB Asset Management AS, Peregrine Capital Management LLC, Louisiana State Employees Retirement System, and Avantax Advisory Services Inc..
View insider buying and selling activity for IQVIA.

How do I buy shares of IQVIA?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IQVIA's stock price today?

One share of IQV stock can currently be purchased for approximately $163.97.

How big of a company is IQVIA?

IQVIA has a market capitalization of $31.36 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. IQVIA employs 67,000 workers across the globe.

What is IQVIA's official website?

The official website for IQVIA is www.iqvia.com.

How can I contact IQVIA?

IQVIA's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.